Pfizer bankrolls an oncolytics biotech upstart with an eye on a future buyout
Pfizer is bankrolling a new oncolytic virus startup, taking a 50% stake in the cancer drug outfit while holding an option to buy it …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
